The role of synthetic drugs in the biologic era: therapeutic strategies for treating juvenile idiopathic arthritis. (23rd March 2016)

• Record Type: Journal Article
• Authors: Hügle, Boris; Horneff, Gerd
• Is Part Of: Expert opinion on pharmacotherapy. Volume 17:Number 5(2016)
• Page Start: 703
• Page End: 714
• Publication Date: 2016-03-23
• Subjects: Hydroxychloroquine -- juvenile idiopathic arthritis -- leflunomide -- methotrexate -- non-steroidal anti-inflammatory drugs -- sulfasalazine -- synthetic DMARDS -- tofacitinib; Chemotherapy -- Periodicals; 615.5805
• DOI: 10.1517/14656566.2016.1133592
• Languages: English
• ISSNs: 1465-6566

Abstract

ABSTRACT: Introduction: Juvenile idiopathic arthritis is the most frequent chronic rheumatic disease in childhood. Synthetic disease modifying drugs (DMARDs) have been used in its treatment since the 1980s and have led to substantial improvement of quality of life and disease outcome. Recent pharmacological research has focused on newer medications, especially biologic agents. Areas covered: Synthetic DMARDS, especially methotrexate, rightfully remain the first-line treatment of most categories of juvenile arthritis, as attested by several international guidelines. A substantial body of evidence supports these medications, and recent research tries to clarify their optimal use in the clinical setting, both as monotherapy and in combination with biologics. In addition, new forms of synthetic DMARDs are in the research pipeline, or are already used for rheumatoid arthritis. Expert Opinion: Methotrexate remains the preferred first-line medication for polyarticular arthritis, with leflunomide as a viable alternative in case of intolerance or toxicity, despite lack of approval in Europe and the US. Sulfasalazine and hydroxychloroquine are used only rarely in clinical practice, considered in combination with methotrexate if biologics are not available. New synthetic DMARDS are in the research pipeline for JIA, in the form of small molecules.